Literature DB >> 30051814

The Burden of Repeat Prescribing Medications after a Related Adverse Drug Event.

Blayne Welk1, Lucie Richard2, Jennifer Winick-Ng3, Salimah Z Shariff4, Kristin K Clemens5.   

Abstract

The use of medications such as glyburide, neuroleptics and benzodiazepines is potentially dangerous in the elderly, as they are linked to adverse drug events such as hypoglycemia and serious falls. We used administrative data from the province of Ontario to determine how often these medications are continued after a patient experiences one of these adverse events. Over a 12-year period, we identified 31,262 patients who had a hospital presentation with hypoglycemia or a fall within three months of starting the previously listed medications. Re-dispensing of these high-risk medications occurred in 55% of patients within six months of the adverse drug event. Among patients with re-dispensed therapies, about 10% had a repeat adverse drug event. These results highlight a common problem that could potentially be addressed with better medication reconciliation and health policies directed at reducing re-dispensing of high-risk medications.
© 2018 Longwoods Publishing.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30051814     DOI: 10.12927/hcq.2018.25526

Source DB:  PubMed          Journal:  Healthc Q        ISSN: 1710-2774


  2 in total

1.  Identifying adverse drug reactions from free-text electronic hospital health record notes.

Authors:  Arthur Wasylewicz; Britt van de Burgt; Aniek Weterings; Naomi Jessurun; Erik Korsten; Toine Egberts; Arthur Bouwman; Marieke Kerskes; René Grouls; Carolien van der Linden
Journal:  Br J Clin Pharmacol       Date:  2021-10-13       Impact factor: 3.716

2.  Using ActionADE to create information continuity to reduce re-exposures to harmful medications: study protocol for a randomized controlled trial.

Authors:  Jeffrey P Hau; Penelope M A Brasher; Amber Cragg; Serena Small; Maeve Wickham; Corinne M Hohl
Journal:  Trials       Date:  2021-02-05       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.